[Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis].
SYMPTOMATIC EFFECTS OF DIACEREIN: Data obtained from several clinical trials have demonstrated that relief of joint pain obtained with the interleukin-1 inhibitor diacerein is comparable with that observed with non-steroidal anti-inflammatory drugs (NSAIDS) after four to six weeks of treatment and that relief persists after treatment withdrawal. Patients taking diacerein are less handicapped, use less NSAID and/or analgesics, and have lower demands for care as well as an improved quality of life. RADIOGRAPHIC FINDINGS: The ECHODIAH study conducted to evaluate the structure-modifying effect of diacerein in hip osteoarthritis.
Drug watch data and clinical trials have confirmed the safety and tolerance of diacerein, so there is no limitation on the duration of its use.
Provvedini
D
D
Laboratoires Negma-Lerads, Toussus le Noble, France.
Cohen
P
P
D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D010003:Osteoarthritis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D016896:Treatment Outcome
D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; C025292:diacerein